Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purified Bee Venom Immunotherapy in Bee Venom Allergy
NCT00263952Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Mar 2003
- Primary completion
- Jan 2005
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apis mellifera venom in bee venom allergy, sponsored by Allergopharma. Primary endpoint: Efficacy of bee venom preparation. Started Mar 2003; status: completed.
02
Drugs
apis mellifera venom
03
Conditions
bee venom allergy
Beyond the preview
Go deeper on NCT00263952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263952.